Wall Street Analysts Are Bullish on Top Healthcare Picks


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Correvio Pharma Corp (CORV), Immune Design (IMDZ) and OpGen Inc (OPGN) with bullish sentiments.

Correvio Pharma Corp (CORV)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Correvio Pharma Corp today and set a price target of $10.50. The company’s shares closed yesterday at $3.60.

According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.4% and a 35.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Correvio Pharma Corp with a $7.60 average price target.

See today’s analyst top recommended stocks >>

Immune Design (IMDZ)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Immune Design, with a price target of $7.75. The company’s shares closed yesterday at $1.49, close to its 52-week low of $1.29.

Pantginis observed:

“Valuation and risks to price target achievement. We reiterate our Buy rating and $7.75 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. We believe upside potential exists as the company explores additional tumor indications for G100, as well as potential contribution from pipeline development. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”

According to TipRanks.com, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -16.2% and a 27.2% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immune Design with a $7.25 average price target.

OpGen Inc (OPGN)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on OpGen Inc today and set a price target of $6. The company’s shares closed yesterday at $1.36, close to its 52-week low of $1.18.

Selvaraju wrote:

“Our price target is derived from a market value of the firm at $79M excluding debt. This includes a discounted cash flow analysis based enterprise value of $80M for the QuickFISH and AMR products, with a 15% discount rate and 2% terminal growth rate.”

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.2% and a 29.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for OpGen Inc with a $6 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts